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Donadio investigated whether the presence of underlying CKD may affect the diagnostic performance of two of the most studied biomarkers of cardio-renal damage, namely neutrophil gelatinase-associated lipocalin (NGAL) and brain natriuretic peptide (BNP) \[[@B1]\]. In this study, plasma NGAL increased in a parallel fashion with the reduction in glomerular filtration rate (GFR), generating a very high number of false positive diagnoses of AKI in stable CKD patients. Conversely, urinary NGAL and plasma BNP were less affected by reduced GFR.

NGAL is a kidney stress protein, the levels of which increase in plasma and urine of patients developing AKI, 2 to 8 hours after renal injuries of various nature \[[@B2]\]. Although the predictive performance of NGAL was remarkable in pediatric populations, conflicting results emerged in the adult setting. In particular, studies reporting an excellent discriminant ability mostly excluded patients with preoperative CKD, whereas a more modest performance was reported in those also including patients with impaired renal function \[[@B3]\]. In CKD patients, NGAL levels are strictly, independently and inversely correlated to residual GFR, probably as the consequence of an active production by the damaged but still vital tubule that goes along with the functional decrease of renal parenchyma \[[@B4]\].

The effect of baseline renal function on the diagnostic performance of urinary NGAL was also evaluated recently by McIlroy and colleagues in a prospective observational study in 426 adults undergoing major cardiac surgery \[[@B5]\]. In patients with baseline GFR \>60 ml/minute who developed AKI, urinary NGAL was higher at all postoperative time points compared with those patients who did not have this complication. Conversely, no differences were reported in patients with baseline GFR \<60 ml/minute. Postoperative NGAL best identified AKI in patients with baseline GFR 90 to 120 ml/minute, therefore suggesting that the optimal discriminatory performance is achieved in patients with normal preoperative renal function.

As is well known, BNP is mostly useful for screening and prognosis of acute and chronic heart dysfunction. Although less than 5% of BNP is cleared by the renal route, accruing evidence indicates that the circulating levels of this biomarker are elevated in CKD patients despite an apparently conserved ventricular function \[[@B6],[@B7]\]. In addition, elevated BNP levels predict accelerated progression of CKD in patients with mild to moderate renal impairment, independently from cardiac (dys)function \[[@B8]\]. Although BNP levels could therefore be helpful in the management of combined heart and kidney disease, these observations might raise concerns regarding the specificity of BNP as biomarker of AHF in the scenario of CKD. Challenging the issue of baseline renal function is thus crucial for validating the potential usefulness of biomarkers in clinical practice. Even the measurement of widely implemented biomarkers, such as troponins or tumor markers \[[@B9],[@B10]\], often leads to misleading clinical interpretations in CKD (especially dialysis) patients.

For biomarkers of AKI and AHF, we believe that, as a general rule, one size (that is, one threshold) cannot fit all. In other words, it is virtually impossible to consider univocal cutoff values able to stratify the risk of AKI or AHF in a miscellaneous population of critically ill patients as a whole. Considering different diagnostic thresholds for different CKD strata might help to improve the overall performance of NGAL and BNP but, predictably, this would not reduce the ground noise caused by other confounders. For instance, apart from renal damage, NGAL levels are known to be affected also by proteinuria, systemic inflammation, oxidative stress, iron balance, diabetes and existing cardiovascular disease \[[@B11]\], while BNP can be influenced by chronic heart failure, obesity, inflammation and even age, gender and heart rate \[[@B12]\]. This variation makes it virtually impossible to find baseline values of these biomarkers falling within the normal range, even in ICU patients with normal renal function or early stage CKD. In view of this, a single-time, threshold-based measurement of NGAL or BNP as an exclusive tool for predicting AKI or AHF should probably be called into question. Even if a cost--benefit analysis must always be taken into account, it would be good to verify whether the predictive capacity of a delta value (variation in biomarkers levels between end of procedure and baseline; for example, time of admission in the ICU) would be superior to that of a single biomarker measurement.

In conclusion, the presence of CKD may actually impact upon the diagnostic performance and reliability of biomarkers of acute damage of kidney and heart. This holds true for biomarkers already used in daily clinical practice as well as for those emerging biomarkers whose promising, preliminary findings in homogeneous study cohorts still await an external validation. Since CKD is exceedingly prevalent in ICU patients, taking systematically into account the effect of residual renal function might enhance the diagnostic performance of biomarkers for the risk stratification of cardio-renal complications in critically ill patients.
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